Blue Trust’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
Other funds holding NTLA
Blue Trust's NTLA Position: Q3 2026 in Review
Blue Trust opened a new position in Intellia Therapeutics (NTLA) in Q3 2026: 7 shares worth $84. The stake represents ﹤0.01% of the portfolio and ranks #2433 among its holdings. This is a return to the name: Blue Trust previously reported a position in NTLA as recently as Q3 2025.
Blue Trust first reported a position in NTLA in Q3 2022 and has held it in 12 quarters since. The position peaked at $93.8K in Q3 2024. 244 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.
- Blue Trust held 7 shares of Intellia Therapeutics worth $84 as of Q3 2026.
- Intellia Therapeutics was a new Blue Trust position in Q3 2026.
- Intellia Therapeutics made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #2433 holding.
- Blue Trust first reported a position in Intellia Therapeutics in Q3 2022 and has held it in 12 quarters since.
- Blue Trust's Intellia Therapeutics position peaked at $93.8K in Q3 2024.
- 244 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.
Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.